

Methylphenidate for Apathy in Community-Dwelling Older Veterans With Mild Alzheimer's Disease: A Double-Blind, Randomized, Placebo-Controlled Trial

Prasad R. Padala, M.D., M.S., Kalpana P. Padala, M.D., M.S., Shelly Y. Lensing, M.S., Daniel Ramirez, M.S., Varun Monga, M.D., Melinda M. Bopp, B.S., Paula K. Roberson, Ph.D., Richard A. Dennis, Ph.D., Frederick Petty, M.D., Ph.D., Dennis H. Sullivan, M.D., William J. Burke, M.D.

Objective: Apathy is a common behavioral problem in Alzheimer's disease. Apathy has profound consequences, such as functional impairment, higher service utilization, higher caregiver burden, and increased mortality. The authors' objective was to study the effects of methylphenidate on apathy in Alzheimer's disease.

Method: A 12-week, prospective, double-blind, randomized, placebo-controlled trial (methylphenidate versus placebo) was conducted in community-dwelling veterans (N=60) with mild Alzheimer's disease. The primary outcome for apathy (Apathy Evaluation Scale–Clinician) and secondary outcomes for cognition (Mini-Mental State Examination, Modified Mini-Mental State Examination), functional status (activities of daily living, instrumental activities of daily living), improvement and severity (Clinical Global Impressions Scale [CGI]), caregiver burden (Zarit Burden Scale), and depression

(Cornell Scale for Depression in Dementia) were measured at baseline and at 4, 8, and 12 weeks.

Results: Participants were all men (77 years old, SD=8). After adjusting for baseline, the methylphenidate group had significantly greater improvement in apathy than the placebo group at 4 weeks, 8 weeks, and 12 weeks. At 12 weeks, there was also greater improvement in cognition, functional status, caregiver burden, CGI scores, and depression in the methylphenidate group compared with the placebo group.

Conclusions: Methylphenidate improved apathy in a group of community-dwelling veterans with mild Alzheimer's disease. Methylphenidate also improved cognition, functional status, caregiver burden, CGI scores, and depression.

Am J Psychiatry 2017; 0:1–10; doi: 10.1176/appi.ajp.2017.17030316

Apathy, a profound loss of motivation, is the most common behavioral problem in Alzheimer's disease (1). Apathy is characterized by indifference, disengagement, passivity, and loss of enthusiasm, interest, and empathy. A recent review of behavioral and psychological symptoms of dementia found that apathy was the only one among eleven symptoms with high baseline prevalence, persistence, and incidence over the course of dementia (2). In a population-based study of adults (N=3,626) ages ≥ 65 years, apathy was one of the most persistent symptoms noted during 10-year dementia follow-up (3). Those with apathy had a 62% probability of remaining apathetic after 1 year. Hence, apathy clearly persists if left untreated.

Apathy has profound consequences for both patients and caregivers. The presence of apathy with Alzheimer's disease is associated with functional impairment. Even after controlling for age, education, cognition, and depression (4, 5), those with apathy are 1.9–2.8 times as likely to have deficits in activities of daily living compared with those without apathy (6, 7). In fact, apathy and other behavioral problems may have

more impact on everyday function than cognition (8). Apathetic patients require more management and support, leading to increased caregiver burden and service utilization. Even more alarming is the fact that apathy is associated with higher mortality. In a population-based study, the presence of apathy was linked with 3.1 times higher mortality than those without apathy (3). Hence, it is important to treat apathy. Because apathy affects function, illness trajectory, and mortality, treating it in early dementia while the patient is dwelling in the community could have substantial benefits.

Unfortunately, pharmacological treatment options for apathy are limited. Medications currently approved for Alzheimer's disease have had mixed results in treating apathy. Cholinesterase inhibitors were found to be effective in improving apathy in secondary analyses, but memantine was not (9, 10). Our team and others have found modest improvements in apathy and cognitive correlates with dopaminergic agents (10–15). However, only two of these studies were randomized controlled trials (16). Although of relatively short duration (2 and 6 weeks), both reported favorable

results with use of methylphenidate (11, 14). A crossover randomized controlled trial in moderate Alzheimer's disease (N=13) found that 2 weeks of methylphenidate treatment significantly improved Apathy Evaluation Scale–Informant (AES-I) scores but worsened Neuropsychiatric Inventory apathy scores compared with placebo (11). The other randomized controlled trial in moderate Alzheimer's disease (N=60) found that, compared with placebo, 6 weeks of methylphenidate treatment resulted in significant improvement in the Neuropsychiatric Inventory apathy scores but not in the AES-I scores (14). Both studies demonstrated early effects of methylphenidate and concluded that longer treatment may lead to better response.

The primary objective of the present study was to test the effects of 12 weeks of methylphenidate treatment on apathy in community-dwelling older veterans with mild Alzheimer's disease. The secondary objectives were to explore the effects of methylphenidate on cognition, functional status, caregiver burden, Clinical Global Impressions Scale (CGI) scores (improvement [CGI-I] and severity [CGI-S]), and depression.

METHOD

Study Design and Participation

A 12-week, double-blind, randomized, placebo-controlled trial was conducted at a Department of Veterans Affairs medical center to compare the effects of methylphenidate with placebo on apathy in community-dwelling older veterans with Alzheimer's disease. The protocol was approved by the institutional review board. Participants were recruited via advertisements, presentations to professional and caregiver support groups, provider referral, and patient records search. After appropriate approvals were obtained, a list was generated of all patients seen over the previous 6 years with various dementia diagnoses, living within a zip code, and excluding those with glaucoma and those currently using antipsychotics and stimulants. A total of 979 names were obtained. Letters were sent out in batches of 100 with a number to opt out of telephone calls. Four hundred letters were sent prior to reaching the recruitment goal. Phone calls were made approximately 2 weeks after the letters were mailed. Most initial telephone conversations were with the caregiver. If interested after the study description, caregivers indicated whether the patient had a diagnosis of dementia and issues with loss of motivation. If both problems were affirmed, permission was requested to further prescreen the patient's medical records. Eligible patients and their caregivers were invited for a baseline visit.

Inclusion and Exclusion Criteria

After assessment of capacity to consent and provision of written informed consent, the diagnosis of Alzheimer's dementia was confirmed by the principal investigator (P.R.P., a board-certified geriatric psychiatrist) using clinical history and DSM-IV criteria. Further screening occurred by medical history, physical examination, and tests for apathy and

cognition. Alzheimer's disease patients were included who had a caregiver; scored ≥ 18 on the Mini-Mental State Examination (MMSE) and > 40 on the Apathy Evaluation Scale–Clinician version (AES-C); and, if applicable, were taking stable doses of antidepressants for at least 2 months or taking cholinesterase inhibitors or memantine for at least 4 months. Patients were excluded if they were taking methylphenidate or if they had prior adverse events with methylphenidate; if they were taking other exclusionary medications (amphetamines, antipsychotics, monoamine oxidase inhibitors, or clonidine); if they had frontotemporal dementia, current major depressive disorder, or active psychosis, as determined by the Mini International Neuropsychiatric Interview (MINI) (17); or if they had a history of uncontrolled seizures, uncontrolled hypertension, symptomatic cardiovascular disease or cardiomyopathy, Tourette's syndrome, or closed-angle glaucoma.

Study Intervention

After baseline data collection (demographic, anthropometric, outcome measures), participants were randomized to methylphenidate (N=30) or placebo (N=30) groups using a random block design developed by a statistician using sealed envelopes. The participants, study team, and outcome assessors were masked to treatment assignment. Study medication was counted and dispensed by the research pharmacy. All participants were started on 5 mg of methylphenidate (or look-alike placebo) twice daily and titrated to 10 mg twice daily at 2 weeks. The first dose was taken early in the morning and the second dose no later than 3 p.m. to avoid sleep disturbance. Participants were instructed not to make up missed doses. The protocol allowed the study physician to decrease the dose if adverse events were reported. Otherwise, participants continued to take 10 mg twice daily until 12 weeks, at which time the dose was tapered to 5 mg twice daily for 3 days and stopped.

Outcome Measures

The primary outcome measure was score on the AES-C. The secondary outcome measures were scores on the Modified Mini-Mental State Examination (3MS) and on the MMSE; instrumental activities of daily living; activities of daily living; scores on the Zarit Burden Scale, the CGI-I and CGI-S scales, and the Cornell Scale for Depression in Dementia (dementia depression scale); and adverse events. Assessments were conducted at the medical center by a trained study team blind to whether drug or placebo was administered. Apathy scale ratings were performed by clinicians, and staff performed the remaining ratings. Interrater reliability was confirmed periodically. The AES-C was measured at baseline and at 4, 8, and 12 weeks. The 3MS, MMSE, CGI-I, CGI-S, weight, and vital signs were measured at baseline and at 4 and 12 weeks, while activities of daily living, instrumental activities of daily living, the Zarit Burden Scale, and the dementia depression scale were measured at baseline and at 8 and 12 weeks. Electrocardiogram tests were obtained at baseline and at 4 and 8 weeks.

Apathy

The AES-C is an 18-item scale that measures behavioral, cognitive, and emotional domains of apathy in the previous 4 weeks. A clinician gathers information from both the patient and caregiver using a semistructured interview. Scores range from 18 to 72, with 30 or higher generally considered clinically significant. A cutoff of 40 has been suggested in patients with dementia (18). The AES-C has good internal consistency (Cronbach's $\alpha=0.94$) and retest reliability ($r=0.94$) (19). Although clear data on clinically meaningful difference are unavailable, a change score of 3.3 is generally considered a meaningful improvement (12). Domains of apathy are calculated by summing scores of pertinent items (19).

Cognition

The 3MS is a screen for global cognition that assesses orientation, registration, recall, simple language, and construction. Retest reliability ranges from 0.91 to 0.93 (20). The scores range from 30 to 100 and are superior to the MMSE as a screen for dementia (21). Different versions were used at each visit to minimize practice effects. An MMSE score derived from the 3MS was used for study inclusion (20).

Function

The instrumental activities of daily living scale assesses eight domains of higher functions necessary to live independently, such as cooking, shopping, and managing medications and finances. Scores range from 0 to 23, with higher scores indicating better function (22). The activities of daily living scale assesses independence in performing basic tasks, such as feeding, dressing, and bathing. Scores range from 0 to 24, with higher scores indicating better function (23).

Caregiver Burden

The Zarit Burden Scale is a widely used 22-item assessment of the caregiver's burden related to patient relationship, general medical and mental health, finances, and social life. Caregivers rate items from 0 (never) to 4 (nearly always), and higher scores indicate higher burden. This scale has excellent reliability (24).

CGI

The CGI is an observational global evaluation that assesses the change in degree of illness relative to an original assessment (25). Two components are evaluated, overall clinical severity (CGI-S) and improvement (CGI-I). At intake, CGI-S scores were rated, as only severity can be rated. In subsequent assessments, both severity and improvement were rated.

Depression

The Cornell Scale for Depression in Dementia is validated for quantifying depression in dementia. It has 19 items, each rated as 0 (absent), 1 (mild or intermittent), or 2 (severe). A score of ≥ 9 indicates depression in dementia (26). In a review of more than 3,000 elderly outpatients with dementia, this scale had a sensitivity of 0.84 and a specificity of 0.80 (27).

Adverse Event Monitoring


Data on adverse events were collected at in-person and telephone visits. Known adverse events associated with methylphenidate listed in the package insert were tabulated, and open-ended questions were asked to identify unexpected adverse events.

Statistical Analyses

Demographics and baseline characteristics were compared using *t* tests or nonparametric Wilcoxon rank sum tests (continuous data) and Fisher's exact test (categorical data). Changes from baseline at 4, 8, and 12 weeks in primary and secondary outcomes, as well as apathy domains (cognitive, behavioral, emotional, motivation, persistence, and novelty), were analyzed using repeated-measures mixed model analyses of covariance. Group (methylphenidate and placebo) and time (4, 8, and 12 weeks), as well as the interaction between the two, were independent variables; the dependent variable's baseline measure was included as a covariate. In post hoc analyses, groups were compared in terms of change from baseline at 4, 8, and 12 weeks using *t* tests derived from model-based contrasts. Additional comparisons were made to detect within-group improvements. An interaction term was added to the model to evaluate how depression (the dementia depression scale), antidepressants, and cholinesterase inhibitors at baseline modified the treatment effect. In addition, an interaction term was added to the model to evaluate how the history of depression at baseline modifies the treatment effect. Two-sided *p* values less than 0.05 indicated statistical significance. Data were analyzed using SAS Enterprise Guide, version 5.1 (SAS Institute, Cary, N.C.).

RESULTS

Screening, enrollment, and participation information is shown in Figure 1. Following review of recruitment records ($N=400$) and in-person screening ($N=156$), eligible subjects ($N=60$) were randomized to the methylphenidate or placebo groups. One subject withdrew from each arm due to caregiver unavailability. Most participants attended all visits (Figure 1). The study demographics are presented in Table 1. All participants were men, which reflects the veteran population age ≥ 60 years. There were no significant differences between groups with regard to age, race, gender, concomitant medications, or comorbidities, except coronary artery disease (Table 1). Depression was common (58%). No participant met criteria for a current episode of major depressive disorder per the MINI. Concomitant medications and comorbidities are listed in Table 1. There were statistically significant between-group differences at baseline in the AES-C, the activities of daily living scale, the instrumental activities of daily living scale, and the CGI-S. The methylphenidate group had higher apathy scores, lower functional status, and higher CGI-S scores than the placebo group (Table 2). The target dosage (10 mg b.i.d.) was achieved on all participants in the methylphenidate group except in three individuals, where the dosage was reduced to 5 mg b.i.d. because of elevated blood

FIGURE 1. CONSORT Diagram of Participants in a Study of Methylphenidate for Apathy in Veterans With Alzheimer's Disease^a

^a MDD=major depressive disorder; MMSE=Mini-Mental State Examination.

pressure, hospitalization for seizure, and insomnia. The mean final dosage of methylphenidate was 9.5 mg b.i.d.

Primary Outcome: Apathy

There was a significant group-by-time interaction for the primary outcome measure, scores on the AES-C ($p<0.016$), in those completing the study ($N=58$) (Figure 2). There were significant differences over time for apathy in the methylphenidate group ($p<0.001$) but not in the placebo group ($p=0.983$). After adjusting for baseline scores on the AES-C, we found that the methylphenidate group had significantly greater improvement than the placebo group (average between-group differences) at 4 weeks (-5.2 , 95% CI= -9.0 to -1.5 , $p=0.006$), at 8 weeks (-7.2 , 95% CI= -10.9 to -3.5 , $p<0.001$), and at 12 weeks (-9.9 , 95% CI= -13.6 to -6.2 , $p<0.001$) (Table 3). There was significant within-group improvement in scores on the AES-C in both groups at all time points; however, the change in the methylphenidate group was significantly higher than that in the placebo group.

Apathy Domains

Improvement seen in scores on the AES-C in the methylphenidate group was driven by improvements in multiple

apathy domains. The behavioral domain had greater improvement in the methylphenidate group compared with the placebo group at 8 weeks (-2.4 , 95% CI= -3.8 to -1.0 , $p<0.001$) and at 12 weeks (-2.6 , 95% CI= -4.0 to -1.2 , $p<0.001$). Similarly, the cognitive domain showed greater improvement in the methylphenidate group compared with the placebo group at 8 weeks (-1.9 , 95% CI= -3.9 to 0.0 , $p=0.050$) and at 12 weeks (-3.6 , 95% CI= -5.5 to -1.6 , $p<0.001$). Improvement in the emotional domain favoring the methylphenidate group reached statistical significance only at 12 weeks (-1.1 , 95% CI= -1.8 to -0.4 , $p=0.003$). The motivation domain improved significantly in the methylphenidate group compared with the placebo group at 8 weeks (-1.3 , 95% CI= -2.2 to -0.4 , $p=0.009$) and at 12 weeks (-1.6 , 95% CI= -2.5 to -0.6 , $p=0.001$). Greater but nonsignificant improvement in the methylphenidate group was found for the novelty ($p=0.052$) and persistence domains ($p=0.053$) only at 12 weeks.

Secondary Outcome Measures

The methylphenidate group had significantly greater improvement in cognition—3MS (6.1, 95% CI=2.7–9.6, $p=0.001$) and MMSE (2.6, 95% CI=1.1–4.0, $p=0.001$) scores—than the

TABLE 1. Patient Characteristics in a Study of Methylphenidate for Apathy in Veterans With Alzheimer's Disease

Variable	Total (N=60)		Methylphenidate (N=30)		Placebo (N=30)		p ^a
	Mean	SD	Mean	SD	Mean	SD	
Continuous variables							
Age (years)	76.6	7.9	77.0	7.5	76.2	8.5	0.711
Weight (lb.)	190.3	35.0	191.5	39.1	189.0	31.0	0.780
Vital signs							
Pulse (beats/min)	68.1	10.3	66.4	11.0	69.9	9.3	0.190
Systolic blood pressure (mmHg)	125.0	12.8	126.1	12.2	123.8	13.4	0.496
Diastolic blood pressure (mmHg)	70.2	9.6	71.0	9.8	69.4	9.4	0.529
Categorical variables	N	%	N	%	N	%	
Male	60	100.0	30	100.0	30	100.0	>0.999
Race							0.492
Non-Hispanic Caucasian	58	96.7	28	93.3	30	100.0	
Non-Hispanic African American	2	3.3	2	6.7	0	0.0	
Education							0.086
Less than high school	26	43.3	9	30.0	17	56.7	
High school	23	38.3	12	40.0	11	36.7	
Some college/diploma	6	10.0	5	16.7	1	3.3	
Bachelor's degree or higher	5	8.3	4	13.3	1	3.3	
Concomitant medications							
Acetylcholinesterase inhibitors	38	63.3	18	60.0	20	66.7	0.592
Antidepressants	33	55.0	19	63.3	14	46.7	0.195
Memantine	18	30.0	7	23.3	11	36.7	0.260
Comorbidities							
Hypertension	51	85.0	27	90.0	24	80.0	0.472
Hyperlipidemia	45	75.0	23	76.7	22	73.3	0.766
Depression	35	58.3	18	60.0	17	56.7	0.793
Coronary artery disease	28	46.7	18	60.0	10	33.3	0.038
Degenerative joint disease	28	46.7	15	50.0	13	43.3	0.605
Diabetes mellitus	16	26.7	8	26.7	8	26.7	>0.999

^a Categorical data assessed with the chi-square test or with Fisher's exact test. Age was assessed with the t test, and other continuous variables were assessed with the Wilcoxon rank sum test.

TABLE 2. Baseline Measures in Methylphenidate and Placebo Groups in a Study of Treatment for Apathy in Veterans With Alzheimer's Disease


Variable	Total (N=59)		Methylphenidate (N=30)		Placebo (N=29)		p ^a
	Mean	SD	Mean	SD	Mean	SD	
Primary endpoint							
Apathy (Apathy Evaluation Scale—Clinician)	49.8	6.7	51.8	7.1	47.9	5.7	0.024
Secondary endpoints							
Global cognition (Modified Mini-Mental State Examination)	81.3	9.5	80.1	9.0	82.6	10.0	0.327
Cognition (Mini-Mental State Examination)	23.8	2.5	23.7	2.5	24.0	2.6	0.725
Functional status (scale of activities of daily living)	22.1	2.6	21.3	2.7	22.9	2.2	0.006
Functional status (scale of instrumental activities of daily living)	13.4	6.0	11.8	5.5	15.1	6.1	0.033
Caregiver burden (Zarit Burden Scale)	26.9	13.0	28.1	12.9	25.3	13.3	0.456
Clinical Global Impressions severity scale	5.3	0.6	5.5	0.6	5.1	0.6	0.011
Cornell Scale for Depression in Dementia	6.7	3.3	7.1	2.6	6.2	4.0	0.280

^a Assessed with the t test or with the Wilcoxon rank sum test (activities of daily living, instrumental activities of daily living, and Clinical Global Impressions severity scale).

placebo group at 12 weeks (Table 3). Significant between-group differences favored the methylphenidate group at 12 weeks for measures on the scale of instrumental activities of daily living (2.3, 95% CI=0.7–3.9, $p=0.005$), on the Zarit Burden Scale (−5.8, 95% CI=−10.1 to −1.4, $p=0.011$), on the CGI-I (−1.3, 95% CI=−1.9 to −0.6, $p\leq 0.001$), on the CGI-S

(−1.1, 95% CI=−1.6 to −0.6, $p<0.001$), and on the dementia depression scale (−2.5, 95% CI=−4.2 to −0.8, $p=0.004$) (Table 3). CGI-I scores also showed significant between-group difference at 4 weeks (Table 3). There were no between-group differences in weight, pulse, systolic blood pressure, and diastolic blood pressure at 4 weeks or at

FIGURE 2. Apathy Evaluation Scale—Clinician Scores Over Time in Methylphenidate and Placebo Groups in a Study of Treatment for Apathy in Veterans With Alzheimer's Disease



12 weeks. However, there was a significant within-group increase in systolic blood pressure in the methylphenidate group at 12 weeks ($p < 0.001$). There was also a within-group decrease in pulse in the placebo group at 4 weeks ($p = 0.063$), which reached statistical significance at 12 weeks ($p = 0.006$) (Table 3).

In addition, the three-way interaction among dementia depression scale scores and use of antidepressants and cholinesterase inhibitors at baseline with regard to week and treatment group was not significant (analyzed in separate models), indicating that the treatment effect over time did not significantly differ according to these covariates. None of the two-way interactions (covariate by group) were significant ($p = 0.231, 0.133$, and 0.910 , respectively). However, for higher scores on the dementia depression scale, the treatment effect was more pronounced even though the effect fell short of significance. For example, at 12 weeks, the estimated treatment effect (95% CI) was -11.3 at a dementia depression scale score of 8 (highest quartile), compared with -7.0 at a dementia depression scale score of 4 (lowest quartile). Similarly, the treatment effect over time did not significantly differ according to the presence of baseline depression.

Adverse Events

Twenty-two participants experienced adverse events (in the methylphenidate group, $N = 13$; in the placebo group, $N = 9$) (Table 4). There were no deaths, although serious adverse events ($N = 6$) and nonserious adverse events ($N = 22$) occurred. Serious events were related to hospitalizations, although only one was possibly or probably related to study participation (seizure, methylphenidate arm). The most common nonserious events were dizziness and insomnia ($N = 5$ each). Participants ($N = 2$) in the placebo arm experienced severe insomnia. The other nonserious adverse events were of mild to moderate intensity. There were no significant differences in the proportion of participants between groups experiencing adverse events ($p = 0.284$) or serious adverse events ($p = 0.195$).

DISCUSSION

The main objective of the study was to compare the effects of methylphenidate with placebo on apathy in community-dwelling older veterans with mild Alzheimer's disease. There was significantly greater improvement in apathy with methylphenidate compared with placebo after 4 weeks of treatment, and apathy continued to improve with methylphenidate at 8 and 12 weeks, with the highest between-group difference at 12 weeks. The behavioral and cognitive domains improved by 8 weeks, and the emotional domain finally improved at 12 weeks. These results suggest that improvement in the emotional domain may be mediated by improvements in the cognitive and behavioral domains. Similarly, the motivation domain improved as early as 8 weeks, while the persistence and novelty domains did not reach statistical significance even at 12 weeks. Distinct brain circuits may play a role in different domains of apathy (28). Cognitive and behavioral apathy is linked to anterior cingulate dysfunction, and emotional apathy to the anterolateral frontal cortex (29, 30). Although it is not known if methylphenidate acts differentially on dopaminergic input in these areas, specific neuromodulation techniques could be developed to personalize the treatment of apathy.

The methylphenidate group also experienced significantly greater improvement than the placebo group in cognition, functional status, caregiver burden, and depression, although effects were not seen until 12 weeks. The 2.6-point change in MMSE scores at week 12 is comparable to that seen with cholinesterase inhibitors (31).

The results of our study are consistent with the previous two randomized controlled trials of methylphenidate for apathy in Alzheimer's disease (14). These three randomized controlled trials collectively support the dopaminergic hypothesis of apathy. Although the ideal duration of treatment with methylphenidate is unknown, a case for longer duration can be made because the results of these studies were proportional to the duration of treatment, with the highest improvement in apathy and cognition noted with 12-week treatment. Longer duration studies need to be conducted to investigate if the improvement in apathy continues with the duration of treatment or if it plateaus at a certain point.

Several other study factors could have contributed to the robust improvement in apathy and cognition. Participants in the present study were community dwellers and had mild dementia, suggesting that methylphenidate could have had more robust effects when used earlier in the trajectory of neurodegeneration. Another unique feature of our study that may have influenced the results is the gender of the participants. It is recognized that apathy increases with age and much more so in men, possibly from effects of declining testosterone levels (32). Furthermore, gender differences are noted in symptom response to methylphenidate treatment in children with attention deficit hyperactivity disorder, with better response in males (33, 34). Thus, apathy

TABLE 3. Changes From Baseline (4, 8, and 12 Weeks) in Outcomes for Methylphenidate and Placebo Groups, and Group Differences^a

Group Difference by Instrument	Change at 4 Weeks			Change at 8 Weeks			Change at 12 Weeks		
	Mean	95% CI	p ^b	Mean	95% CI	p ^b	Mean	95% CI	p ^b
Apathy Evaluation Scale—Clinician ^c			0.006			<0.001			<0.001
Methylphenidate	-9.7	-12.3 to -7.1		-11.5	-14.1 to -8.9		-14.1	-16.7 to -11.6	
Placebo	-4.4	-7.0 to -1.8		-4.3	-6.9 to -1.7		-4.2	-6.8 to -1.7	
Difference	-5.2	-9.0 to -1.5		-7.2	-10.9 to -3.5		-9.9	-13.6 to -6.2	
Modified Mini-Mental State Examination ^d			0.638						0.001
Methylphenidate	2.3	-0.3 to 4.8					5.7	3.2 to 8.1	
Placebo	1.4	-1.1 to 3.9					-0.5	-2.9 to 2.0	
Difference	0.9	-2.7 to 4.5					6.1	2.7 to 9.6	
Mini-Mental State Examination ^d			0.921						0.001
Methylphenidate	1.0	-0.1 to 2.0					2.2	1.2 to 3.2	
Placebo	1.0	0.0 to 2.1					-0.4	-1.4 to 0.6	
Difference	-0.1	-1.6 to 1.4					2.6	1.1 to 4.0	
Scale of activities of daily living ^e						0.595			0.245
Methylphenidate				0.7	0.1 to 1.3		0.9	0.3 to 1.5	
Placebo				0.4	-0.2 to 1.1		0.4	-0.3 to 1.0	
Difference				0.2	-0.7 to 1.1		0.5	-0.3 to 1.4	
Scale of instrumental activities of daily living ^e						0.222			0.005
Methylphenidate				1.1	0.0 to 2.2		1.7	0.7 to 2.8	
Placebo				0.1	-1.0 to 1.2		-0.6	-1.7 to 0.6	
Difference				1.0	-0.6 to 2.6		2.3	0.7 to 3.9	
Zarit Burden Scale ^e						0.715			0.011
Methylphenidate				-3.6	-6.5 to -0.7		-7.0	-9.8 to -4.1	
Placebo				-4.4	-7.7 to -1.1		-1.2	-4.5 to 2.1	
Difference				0.8	-3.6 to 5.2		-5.8	-10.1 to -1.4	
Cornell Scale for Depression in Dementia ^e						0.114			0.004
Methylphenidate				-1.7	-2.9 to -0.6		-2.7	-3.9 to -1.5	
Placebo				-0.4	-1.6 to 0.8		-0.2	-1.4 to 1.0	
Difference				-1.4	-3.0 to 0.3		-2.5	-4.2 to -0.8	
Clinical Global Impressions improvement scale ^d			0.007						<0.001
Methylphenidate	2.3	1.9 to 2.7					2.4	1.9 to 2.8	
Placebo	3.2	2.7 to 3.6					3.6	3.1 to 4.1	
Difference	-0.9	-1.5 to -0.2					-1.3	-1.9 to -0.6	
Clinical Global Impressions severity scale ^d			0.083						<0.001
Methylphenidate	-1.0	-1.4 to -0.7					-1.5	-1.8 to -1.1	
Placebo	-0.6	-0.9 to -0.3					-0.4	-0.7 to 0.0	
Difference	-0.4	-0.9 to 0.1					-1.1	-1.6 to -0.6	
Weight ^d			0.274						0.167
Methylphenidate	-1.1	-3.0 to 0.7					-1.4	-3.3 to 0.5	
Placebo	0.3	-1.5 to 2.2					0.5	-1.5 to 2.5	
Difference	-1.5	-4.1 to 1.2					-1.9	-4.6 to 0.8	
Pulse ^d			0.661						0.205
Methylphenidate	-2.0	-5.2 to 1.1					-1.9	-5.1 to 1.4	
Placebo	-3.0	-6.3 to 0.2					-5.0	-8.5 to -1.4	
Difference	1.0	-3.5 to 5.5					3.1	-1.7 to 8.0	
Systolic blood pressure ^d			0.799						0.263
Methylphenidate	5.9	-5.0 to 15.0					18.3	7.9 to 28.6	
Placebo	3.2	-7.0 to 13.4					9.3	-2.5 to 21.2	
Difference	1.8	-12.4 to 16.1					8.9	-6.8 to 24.7	

continued

TABLE 3, continued

Group Difference by Instrument	Change at 4 Weeks			Change at 8 Weeks			Change at 12 Weeks		
	Mean	95% CI	p ^b	Mean	95% CI	p ^b	Mean	95% CI	p ^b
Diastolic blood pressure ^d			0.701						0.825
Methylphenidate	0.4	−3.4 to 4.2					2.8	−1.1 to 6.7	
Placebo	−0.6	−4.5 to 3.2					2.1	−2.1 to 6.4	
Difference	1.1	−4.4 to 6.5					0.7	−5.1 to 6.4	

^a All means are estimates from a repeated-measures model of 4-, 8-, and 12-week change from baseline. Differences reflect the change in the methylphenidate group minus the change in the placebo group and are adjusted for the corresponding baseline measure.

^b The p values comparing the methylphenidate and placebo groups are model-based.

^c Measured at baseline and at 4, 8, and 12 weeks.

^d Measured only at baseline and at 4 and 12 weeks.

^e Measured only at baseline and at 8 and 12 weeks.

TABLE 4. Summary of Adverse Events Experienced by Participants in a Study of Treatment for Apathy in Veterans With Alzheimer's Disease

Adverse Event	Total (N=59)		Methylphenidate (N=30)		Placebo (N=29)	
	N	%	N	%	N	%
Total adverse events	22	37	13	43	9	31
Serious adverse events	6	10	5	17	1	3
Hospitalization for pneumonia or flu	3	5	2	7	1	3
Hospitalization for ear surgery	1	2	1	3	0	0
Hospitalization for seizures	1	2	1	3	0	0
Hospitalization for unknown reason	1	2	1	3	0	0
Nonserious adverse events						
Decreased or loss of appetite	1	2	1	3	0	0
Dry mouth	1	2	1	3	0	0
Weight loss	1	2	1	3	0	0
Abdominal pain	3	5	1	3	2	7
Dizziness	5	8	3	10	2 ^a	7
Insomnia	5	8	2	7	3	10
Anxiety	2	3	0	0	2	7
Racing thoughts	1	2	0	0	1	3
Melena	1	2	0	0	1	3
Pneumonia	1	2	1	3	0	0
Shortness of breath	1	2	1	3	0	0
Chest pain	1	2	1	3	0	0
Elevated blood pressure	1	2	1	3	0	0
Nonserious adverse events (open-ended)						
Feeling hollow	2	3	1	3	1	3
Disinhibition	1	2	1	3	0	0
Weight gain	1	2	1	3	0	0
Backache	1	2	1	3	0	0
Pain in extremities	2	3	2	7	0	0
Bruxism	1	2	1	3	0	0
Balance problems	1	2	1	3	0	0
Acute renal failure	1	2	1	3	0	0

^a One participant experienced two episodes.

may improve preferentially among men in response to methylphenidate.

Other differences among the aforementioned three methylphenidate randomized controlled trials may explain the different outcomes. Our study did not include a standardized psychosocial intervention as was done in one of the previous randomized controlled trials (14). The primary outcome measure in our study was the AES-C, whereas the AES-I was used in prior studies (14). The AES-I may not discriminate apathy from depression as well as the AES-C,

and thus, changes in the AES-I could have been confounded by changes in depression scores (19). Furthermore, the variation in the scoring of the AES-I might be influenced more by an interest factor than the apathy factor, which is the main source of variance in the AES-C (18).

A lag in improvement in cognitive and functional outcomes, relative to apathy measures, was noted. The scale of activities of daily living did not change significantly because most participants were high functioning, as expected in a community-dwelling cohort. Caregiver burden improved between groups only at the 12-week mark, suggesting that this result may be a distal outcome influenced by the apathy, cognitive, and functional outcomes. Although the cohort on average was nondepressed according to dementia depression scale cutoffs at baseline, there was improvement in depressive symptoms by

12 weeks. The change in depression scores is similar to what is known with methylphenidate, but the response was delayed (35). Neither the baseline history of depression nor the treatment with antidepressants influenced apathy outcomes, but higher baseline scores on the dementia depression scale were associated with greater treatment effect. This finding illustrates that although there is some overlap between apathy and depression, apathy is a distinct entity warranting additional treatment. Similarly, the treatment effect over time did not significantly differ

Patient Perspective

Report from a caregiver: “How is his get up and go?” was the key question that got us in to the study. Although Martin had Alzheimer’s for 3 years prior to the study, the major problem was his loss of motivation. I had learned over time to handle his forgetting what happened recently, finding his wallet several times a day, reminding him the names of our grandchildren, and completing his sentences for him as he fumbled for the right word. What I was not prepared for was his not wanting to do anything. It was hard for me to see him sitting all day, not helping with chores at home, and expecting me to do things that he was fully capable of doing physically, such as taking his medications, taking out the trash, or simply taking a walk. He had been postponing yard work for about 4 months that he could do in a day. His doctors said that he was not depressed, and I wondered if he was doing this intentionally. When he stopped reading mystery books and writing letters to servicemen in Iraq, which he was

passionate about before, I knew that his motivation had “got up and went” and that we needed help.

Martin decided to participate in the study mostly to please me but noticed the change in his energy levels right away. “I guess you don’t know what you are missing until things get better” is what he said after being in the study for a couple of weeks. He had more energy and ambition and was more spontaneous than he was in the previous couple of years. He was taking fewer naps during the day and even dabbled in writing the servicemen. I think he liked going to the research visits and had more motivation by the second month of the study. He also spent more time with our grandchildren. The yard work is still pending and I still help him with his medications, but we went to church together last Sunday, which we had not done over the last 2 years. Martin was not motivated to get ready in the mornings, and I had gotten used to going to church by myself. I told the study team that they gave me my husband back. I cannot thank them enough for the same.

according to cholinesterase inhibitor treatment at baseline. This finding hints at additional benefit that stimulants could offer for apathy, over and above the effect of cholinesterase inhibitors. Weight loss, changes in heart rate and blood pressure, and insomnia are common side effects of methylphenidate that prevent its use. In the present study, there were no between-group differences in these measures. However, those receiving methylphenidate were noted to have statistically and perhaps clinically significant change in systolic blood pressure (median increase of 7 mmHg). This finding agrees with other published reports (36). In our study, the baseline systolic blood pressure and change in systolic blood pressure did not vary per group. Although there is no evidence of a statistical interaction, it is possible that the presence of hypertension at baseline does make it more likely for increased systolic blood pressure at follow-up due to the sympathomimetic action of methylphenidate.

The major strength of the study is its design: a double-blind, randomized, placebo-controlled trial in community-dwelling older veterans with mild Alzheimer’s disease. Other strengths include that the medications were well tolerated and that there were few dropouts ($N=2$). However, the study has several limitations. This study was conducted in a select group (veterans), and all participants were men. The study was also conducted at a single site and had a small sample size. The study also lacked biomarkers.

In conclusion, 12-week methylphenidate treatment improved apathy in community-dwelling older veterans with mild Alzheimer’s disease. Methylphenidate also improved cognition, functional status, caregiver burden, CGI scores (improvement and severity), and depression.

AUTHOR AND ARTICLE INFORMATION

From the Geriatric Research, Education, and Clinical Center, Central Arkansas Veterans Healthcare System, Little Rock; the Departments of Psychiatry, of Geriatrics, and of Biostatistics, University of Arkansas for Medical Sciences, Little Rock; the School of Pharmacy and Health Professions, Creighton University, Omaha; Banner Thunderbird Medical Center, Glendale, Ariz.; Orlando VA Medical Center, Orlando, Fla.; the University of Central Florida College of Medicine, Orlando; and Banner Alzheimer’s Institute, University of Arizona College of Medicine, Phoenix.

Address correspondence to Dr. Prasad Padala (prasad.padala@va.gov).

Presented in part at the annual scientific meeting of the Academy of Psychosomatic Medicine, 2011; at the VA National Mental Health Conference, Baltimore, 2011; at the annual meeting of the International Psychogeriatrics Association, The Hague, Netherlands, 2011; at the International Conference on Alzheimer’s Disease, Paris, 2011; and at the annual scientific meeting of the American Geriatric Society, Washington, D.C., 2011.

Supported by a VA Merit Review Entry Program grant to Dr. Prasad Padala. The sponsor had no role in the design, methods, subject recruitment, data collection, analysis, or preparation of the article.

The authors thank Subhash C. Bhatia, M.D., and Elisabeth H. Chandler, Pharm.D., for support in the conduct of the study and the ADMET2 steering committee for its encouragement.

Clinicaltrials.gov identifier: NCT00495820.

Dr. Burke has received research support from NIMH, the National Institute on Aging, the Alzheimer’s Association, the Alzheimer’s Disease Cooperative Study, and the Alzheimer’s Therapeutic Research Institute; and he has been on the data monitoring committee of Otsuka and a consultant to Eli Lilly, FORUM Pharmaceuticals, and Forest. The Banner Alzheimer’s Institute has received support from AbbVie, Accera, AstraZeneca, AVID, Axovant, Biogen, Elan, Eli Lilly, Genentech, Global Alzheimer’s Platform, Janssen, Lundbeck, Merck, Novartis, Pfizer, Roche, Takeda, Toyama Chemical, and Suven. The other authors report no financial relationships with commercial interests.

Received March 16, 2017; revision received May 9, 2017; accepted May 18, 2017.

REFERENCES

1. Lancôt KL, Agüera-Ortiz L, Brodaty H, et al: Apathy associated with neurocognitive disorders: recent progress and future directions. *Alzheimers Dement* 2017; 13:84–100
2. van der Linde RM, Denning T, Stephan BC, et al: Longitudinal course of behavioural and psychological symptoms of dementia: systematic review. *Br J Psychiatry* 2016; 209:366–377
3. van der Linde RM, Matthews FE, Denning T, et al: Patterns and persistence of behavioural and psychological symptoms in those with cognitive impairment: the importance of apathy. *Int J Geriatr Psychiatry* 2017; 32:306–315
4. Clarke DE, Ko JY, Lyketsos C, et al: Apathy and cognitive and functional decline in community-dwelling older adults: results from the Baltimore ECA longitudinal study. *Int Psychogeriatr* 2010; 22:819–829
5. Onyike CU, Sheppard JM, Tschanz JT, et al: Epidemiology of apathy in older adults: the Cache County Study. *Am J Geriatr Psychiatry* 2007; 15:365–375
6. Freels S, Cohen D, Eisdorfer C, et al: Functional status and clinical findings in patients with Alzheimer's disease. *J Gerontol* 1992; 47: M177–M182
7. Okura T, Plassman BL, Steffens DC, et al: Prevalence of neuropsychiatric symptoms and their association with functional limitations in older adults in the United States: the aging, demographics, and memory study. *J Am Geriatr Soc* 2010; 58:330–337
8. Rog LA, Park LQ, Harvey DJ, et al: The independent contributions of cognitive impairment and neuropsychiatric symptoms to everyday function in older adults. *Clin Neuropsychol* 2014; 28:215–236
9. Cummings JL, Koumaras B, Chen M, et al: Effects of rivastigmine treatment on the neuropsychiatric and behavioral disturbances of nursing home residents with moderate to severe probable Alzheimer's disease: a 26-week, multicenter, open-label study. *Am J Geriatr Pharmacother* 2005; 3:137–148
10. Zhang N, Wei C, Du H, et al: The effect of memantine on cognitive function and behavioral and psychological symptoms in mild-to-moderate Alzheimer's disease patients. *Dement Geriatr Cogn Disord* 2015; 40:85–93
11. Herrmann N, Rothenburg LS, Black SE, et al: Methylphenidate for the treatment of apathy in Alzheimer disease: prediction of response using dextroamphetamine challenge. *J Clin Psychopharmacol* 2008; 28:296–301
12. Lancôt KL, Chau SA, Herrmann N, et al: Effect of methylphenidate on attention in apathetic AD patients in a randomized, placebo-controlled trial. *Int Psychogeriatr* 2014; 26:239–246
13. Padala PR, Burke WJ, Shostrom VK, et al: Methylphenidate for apathy and functional status in dementia of the Alzheimer type. *Am J Geriatr Psychiatry* 2010; 18:371–374
14. Rosenberg PB, Lancôt KL, Drye LT, et al: Safety and efficacy of methylphenidate for apathy in Alzheimer's disease: a randomized, placebo-controlled trial. *J Clin Psychiatry* 2013; 74:810–816
15. Teng E, Becker BW, Woo E, et al: Utility of the functional activities questionnaire for distinguishing mild cognitive impairment from very mild Alzheimer disease. *Alzheimer Dis Assoc Disord* 2010; 24: 348–353
16. Baloh RW, Corona S, Jacobson KM, et al: A prospective study of posturography in normal older people. *J Am Geriatr Soc* 1998; 46: 438–443
17. Sheehan DV, Lecrubier Y, Sheehan KH, et al: The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. *J Clin Psychiatry* 1998; 59(suppl 20):22–33
18. Clarke DE, Reekum Rv, Simard M, et al: Apathy in dementia: an examination of the psychometric properties of the apathy evaluation scale. *J Neuropsychiatry Clin Neurosci* 2007; 19:57–64
19. Marin RS, Biedrzycki RC, Firinciogullari S: Reliability and validity of the Apathy Evaluation Scale. *Psychiatry Res* 1991; 38:143–162
20. Teng EL, Chui HC: The Modified Mini-Mental State (3MS) examination. *J Clin Psychiatry* 1987; 48:314–318
21. McDowell I, Kristjansson B, Hill GB, et al: Community screening for dementia: the Mini Mental State Exam (MMSE) and Modified Mini-Mental State Exam (3MS) compared. *J Clin Epidemiol* 1997; 50:377–383
22. Lawton MP, Brody EM: Assessment of older people: self-maintaining and instrumental activities of daily living. *Gerontologist* 1969; 9: 179–186
23. Katz S, Ford AB, Moskowitz RW, et al: Studies of illness in the aged: the index of ADL: a standardized measure of biological and psychosocial function. *JAMA* 1963; 185:914–919
24. Zarit SH, Reever KE, Bach-Peterson J: Relatives of the impaired elderly: correlates of feelings of burden. *Gerontologist* 1980; 20: 649–655
25. Guy W (ed): ECDEU Assessment Manual for Psychopharmacology: Publication (ADM) 76-338. Rockville, Md, US Department of Health, Education, and Welfare, 1976, pp 218–222
26. Alexopoulos GS, Abrams RC, Young RC, et al: Cornell Scale for Depression in Dementia. *Biol Psychiatry* 1988; 23:271–284
27. Goodarzi ZS, Mele BS, Roberts DJ, et al: Depression case finding in individuals with dementia: a systematic review and meta-analysis. *J Am Geriatr Soc* 2017; 65:937–948
28. Sultzer DL, Leskin LP, Jacobs ZM, et al: Cognitive, behavioral, and emotional domains of apathy in Alzheimer's disease: clinical and neurobiological features. *Am J Geriatr Psychiatry* 2013; 21(suppl): S144–S145
29. Robert PH, Darcourt G, Koulibaly MP, et al: Lack of initiative and interest in Alzheimer's disease: a single photon emission computed tomography study. *Eur J Neurol* 2006; 13:729–735
30. Benoit M, Claret S, Koulibaly PM, et al: Brain perfusion correlates of the apathy inventory dimensions of Alzheimer's disease. *Int J Geriatr Psychiatry* 2004; 19:864–869
31. Rogers SL, Farlow MR, Doody RS, et al: A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. *Neurology* 1998; 50:136–145
32. Brodaty H, Altendorf A, Withall A, et al: Do people become more apathetic as they grow older? A longitudinal study in healthy individuals. *Int Psychogeriatr* 2010; 22:426–436
33. Huang YS, Wang LJ, Chen CK: Long-term neurocognitive effects of methylphenidate in patients with attention deficit hyperactivity disorder, even at drug-free status. *BMC Psychiatry* 2012; 12:194
34. Krell-Roesch J, Pink A, Roberts RO, et al: Timing of physical activity, apolipoprotein E ϵ 4 genotype, and risk of incident mild cognitive impairment. *J Am Geriatr Soc* 2016; 64:2479–2486
35. Emptage RE, Semla TP: Depression in the medically ill elderly: a focus on methylphenidate. *Ann Pharmacother* 1996; 30:151–157
36. Hennissen L, Bakker MJ, Banaschewski T, et al: Cardiovascular effects of stimulant and non-stimulant medication for children and adolescents with ADHD: a systematic review and meta-analysis of trials of methylphenidate, amphetamines and atomoxetine. *CNS Drugs* 2017; 31:199–215